Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Inozyme Pharma Inc (INZY)

Inozyme Pharma Inc (INZY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 185,011
  • Shares Outstanding, K 64,240
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,170 K
  • EBIT $ -100 M
  • EBITDA $ -104 M
  • 60-Month Beta 1.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.42

Options Overview Details

View History
  • Implied Volatility 277.50% ( +9.47%)
  • Historical Volatility 59.70%
  • IV Percentile 99%
  • IV Rank 81.05%
  • IV High 333.68% on 11/14/24
  • IV Low 37.16% on 05/20/24
  • Put/Call Vol Ratio 0.29
  • Today's Volume 22
  • Volume Avg (30-Day) 112
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,200
  • Open Int (30-Day) 2,282

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 7
  • High Estimate -0.33
  • Low Estimate -0.47
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.75 +2.18%
on 11/19/24
5.59 -49.73%
on 10/21/24
-2.73 (-49.28%)
since 10/18/24
3-Month
2.75 +2.18%
on 11/19/24
6.24 -54.97%
on 09/17/24
-2.05 (-42.18%)
since 08/19/24
52-Week
2.75 +2.18%
on 11/19/24
7.80 -63.95%
on 04/01/24
-0.45 (-13.80%)
since 11/17/23

Most Recent Stories

More News
Inozyme Pharma to Present at Upcoming Investor Conferences

INZY : 2.81 (-2.43%)
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

INZY : 2.81 (-2.43%)
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

INZY : 2.81 (-2.43%)
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

INZY : 2.81 (-2.43%)
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

INZY : 2.81 (-2.43%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...

INZY : 2.81 (-2.43%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...

INZY : 2.81 (-2.43%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...

INZY : 2.81 (-2.43%)
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...

ACHN : 0.7912 (-21.66%)
ARVN : 21.64 (-6.68%)
NXTC : 1.3100 (+1.55%)
BHVN : 46.30 (+1.96%)
INZY : 2.81 (-2.43%)
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...

INZY : 2.81 (-2.43%)

Business Summary

Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston,...

See More

Key Turning Points

3rd Resistance Point 3.12
2nd Resistance Point 3.04
1st Resistance Point 2.92
Last Price 2.81
1st Support Level 2.72
2nd Support Level 2.64
3rd Support Level 2.52

See More

52-Week High 7.80
Fibonacci 61.8% 5.87
Fibonacci 50% 5.27
Fibonacci 38.2% 4.68
Last Price 2.81
52-Week Low 2.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar